Industry News
Pharmaceutical Industry News
CMI Media Group’s Jose Ferreira…
CMI Media Group’s Jose Ferreira on AI, omnichannel orchestration and delivering value in the moment for HCPs and consumers.
AI-driven search, zero-click…
AI-driven search, zero-click behavior and why context now defines pharma marketing success.
Why proactive evidence generation…
Why proactive evidence generation and coordination are critical for medical affairs teams to stand out.
With a better-than-expected first…
With a better-than-expected first quarter in the books, Pfizer—continuing to grapple with the post-pandemic overhang from its COVID-19 franchise—is sticking with the sales forecast it set earlier this year, raising questions from at least one
Novartis is continuing its…
Novartis is continuing its multiyear overhaul with new plans to shutter its production facility in Wehr, Germany, by 2028. The move, announced Tuesday, will eliminate about 220 jobs, according to Novartis.
The German vaccine maker plans to…
The German vaccine maker plans to wind down operations at a handful of its sites in Germany plus one in Singapore, putting as many as 1,860 jobs on the chopping block.
Fresh off gaining an FDA expansion…
Fresh off gaining an FDA expansion for Auvelity as a treatment for agitation associated with Alzheimer’s disease, Axsome Therapeutics has projected peak sales for the non-antipsychotic drug to reach $8 billion.
Why consent, timing and…
Why consent, timing and closed-loop measurement are redefining how pharma brands engage HCPs.
Sanofi is supercharging its…
Sanofi is supercharging its artificial intelligence capabilities. The French pharma is investing $294 million to expand its global AI center of excellence in Toronto, kicking off a scale-up of the digital infrastructure it built at
Neurocrine Biosciences has shared…
Neurocrine Biosciences has shared survey data showing how tardive dyskinesia affects the ability of patients and caregivers to work, supporting the company’s case for timely treatment of the movement disorder.
Kyverna Therapeutics is on the…
Kyverna Therapeutics is on the cusp of a historic first: getting a CAR-T therapy approved for an autoimmune disease—and now it’s looking to boost its commercial chops as it nears the finish line.
Created from the merger of…
Created from the merger of Mallinckrodt and Endo last year, Keenova is launching its first Dupuytren's contracture campaign under its new moniker.
Kennedy Starts a Push to Help Americans Quit Antidepressants
The health secretary has long complained that Americans overuse psychiatric medications. New policies he is introducing aim to change that.
Cytokinetics has aced a phase 3…
Cytokinetics has aced a phase 3 trial of Myqorzo in patients with non-obstructive hypertrophic cardiomyopathy. The South San Francisco company is bidding to make Myqorzo the first treatment approved in the indication.
Though largely operating in the…
Though largely operating in the background until recently, Prolific Machines’ optogenetic approach to biomanufacturing is set to make waves thanks to the achievement of an impressive milestone in monoclonal antibody manufacturing.
The U.S. Supreme Court has…
The U.S. Supreme Court has temporarily reinstated online access to the abortion pill mifepristone after a federal appeals court in New Orleans ruled to prevent mifepristone from being prescribed over the phone and sent through
The company chalks up a financial…
The company chalks up a financial impact of about 150 billion Korean won ($102 million) from "preemptive production adjustments" made to mitigate potential manufacturing impacts, a spokesperson said.
After submitting plans to cut 114…
After submitting plans to cut 114 jobs tied to its U.S. headquarters in New Jersey in March, Novartis late last month added a handful of additional roles from the East Hanover site to its multiyear
Bristol Myers Squibb is warming up…
Bristol Myers Squibb is warming up for the FIFA World Cup 2026 with a new media campaign, launching its “Won’t Lose” ad ahead of the soccer community arriving in the U.S. for this summer’s tournament.
After topping up its long-running…
After topping up its long-running operations in Puerto Rico last year, Amgen is infusing $300 million more into the U.S. territory.